Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1081-1100 of 3,900 trials

Recurrent Gynecological Cancers: IMGN151 Study

We are testing a new drug, IMGN151, in women with recurrent gynecological cancers to assess its safety and determine the best dose. This study aims to understand how well the drug works and its effects on patients.

Recurrent Gynecological Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Mycobacterium Xenopi Infection: ARIKAYCE Inhalation Treatment

We are studying whether adding ARIKAYCE to standard treatment helps people with Mycobacterium xenopi lung infections clear the infection more effectively. The trial will measure how quickly and effectively the treatment works compared to standard care alone.

Mycobacterium xenopi Pulmonary Infection>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Chronic Kidney Disease: Teriparatide for Bone Health

We are studying whether teriparatide can improve bone metabolism in patients with chronic kidney disease and adynamic bone disorder. This trial compares the effects of treatment to no treatment at all.

Adynamic Bone Disorder>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNephrologyOrthopedics and Traumatology

Solid Tumors: IMA401 TCER® Treatment

We are testing a new bispecific T-cell receptor treatment for patients with solid tumors. The study looks at its effects alone and with a checkpoint inhibitor to see how well it works.

Solid Tumors>2 yearsSafety phase (I)Oncology

Severe Corneal Ulcers: NANOULCOR Treatment

We are studying an artificial cornea model for patients with severe corneal ulcers that don't respond to regular treatments. The goal is to see if it helps heal the ulcers and improves vision.

Corneal Ulcer≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Metastatic Prostate Cancer: ProBio Study

We are investigating if treatment choices based on biomarker signatures can improve survival and quality of life for patients with metastatic prostate cancer. This study compares these personalized approaches to standard care.

Metastatic Prostate CancerConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Staphylococcus Aureus Bacteraemia: Bensylpenicillin vs. Cloxacillin

We are comparing two antibiotics to see which one works better for patients with a specific bacterial infection. The study looks at treatment outcomes, relapse rates, and side effects.

Staphylococcus aureus Bacteraemia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Chronic Hepatitis B: Long-Term Study on Treatment Response

We are investigating how well previous participants of a hepatitis B treatment maintain their health over time. This study focuses on those who have stopped certain therapies and aims to understand their long-term outcomes.

Chronic Hepatitis BEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyInfectious Diseases

Multiple Myeloma: Etentamig with Cancer Treatments

We are studying a new drug, Etentamig, combined with standard cancer therapies for adults with relapsed or refractory multiple myeloma. The goal is to assess its safety and impact on disease activity.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Heart Attack Recovery: Ziltivekimab Study

We are investigating how ziltivekimab may improve heart health in people who have had a heart attack compared to a placebo. This study aims to see if it can reduce serious heart-related issues.

Heart Attack>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteCardiologyInternal Medicine

Late Renal Graft Failure: Immunosuppression Study

We are comparing the effects of continuing versus stopping immunosuppression in patients with late renal graft failure. This study aims to see how these approaches impact health outcomes over two years.

Kidney Transplant>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineNephrology

Chronic Obstructive Pulmonary Disease: GSK3862995B Study

We are investigating a new treatment for Chronic Obstructive Pulmonary Disease in both healthy individuals and those with the condition. This study aims to understand how the treatment may work in different populations.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsSafety phase (I)Pulmonology

Rectal Adenocarcinoma: Contact X-Ray Brachytherapy Study

We are studying whether adding contact X-ray brachytherapy to standard treatment can help preserve the rectum and improve survival in patients with intermediate substage rectal adenocarcinoma. We will also assess its impact on quality of life and side effects.

Rectal Adenocarcinoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Alectinib Dosing: Standard vs. Personalized Approach

We are comparing standard alectinib dosing to a personalized dosing method based on blood levels for patients with specific alectinib concentrations. The goal is to see if personalized dosing improves treatment outcomes and safety.

ALK Positive Non-Small Cell Lung Cancer1-2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Liver Cancer: Fecal Microbiota Transfer Study

We are investigating whether fecal microbiota transfer can help liver cancer patients who are resistant to standard treatments. The study aims to improve immune response and overall survival.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesHepatologyInternal MedicineOncology

Metastatic Breast Cancer: BGB-43395 Study

We are investigating a new drug for patients with metastatic HR+/HER2- breast cancer and other advanced solid tumors. The study aims to evaluate its safety and early signs of effectiveness, both alone and with other treatments.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Lung Cancer: Durvalumab and Domvanalimab Study

We are studying a combination of two medications for patients with stage III unresectable non-small cell lung cancer who have not progressed after initial treatment. The goal is to see if this combination improves survival and disease control compared to standard treatment.

Lung Cancer6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Follicular Lymphoma: Epcoritamab with Rituximab and Lenalidomide

We are studying a new treatment combination for adults with previously untreated follicular lymphoma. The goal is to see if it works better and has fewer side effects than standard chemotherapy.

Follicular LymphomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Oocyte Donation: Corifollitropin alfa vs. Daily rFSH

We are studying whether Corifollitropin alfa can help increase the number of eggs collected from oocyte donors compared to standard daily treatments. This trial involves women using hormone suppression to improve egg quality.

Female Infertility1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and Obstetrics

Cleft Palate Treatment: Tissue-Engineered Oral Mucosa Substitute

We are testing a new tissue-engineered substitute for patients with cleft palate to see if it is safe and effective for healing and improving quality of life. The study will compare outcomes with standard treatments.

Cleft Lip and Palate>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyOrthopedics and TraumatologyPediatrics